Yubo International Biotech Limited
YBGJ
$0.053
$0.00367.29%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -99.43% | -96.05% | 90.00% | 85.47% | 483.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.43% | -96.05% | 90.00% | 85.47% | 483.70% |
| Cost of Revenue | 13.14% | -0.09% | 53.03% | -37.40% | 264.34% |
| Gross Profit | -149.71% | -145.27% | 144.08% | 258.28% | 698.48% |
| SG&A Expenses | 11.83% | 142.05% | 142.13% | 49.61% | 11.38% |
| Depreciation & Amortization | -3.58% | 196.30% | 468.39% | 618.35% | 588.77% |
| Other Operating Expenses | 9.55% | -1.23% | -21.06% | 14.85% | 36.32% |
| Total Operating Expenses | 9.96% | 76.74% | 86.18% | 46.43% | 37.88% |
| Operating Income | -65.61% | -272.65% | -85.06% | -36.28% | 0.71% |
| Income Before Tax | -65.83% | -273.85% | -85.57% | -36.60% | 0.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.83% | -273.85% | -85.57% | -36.60% | 0.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.55% | -248.89% | -72.99% | -33.19% | 0.82% |
| EBIT | -65.61% | -272.65% | -85.06% | -36.28% | 0.71% |
| EBITDA | -78.64% | -286.07% | -62.87% | -16.14% | 14.51% |
| EPS Basic | -48.48% | -253.19% | -72.06% | -31.65% | 2.94% |
| Normalized Basic EPS | -36.51% | -222.58% | -61.36% | -27.45% | 3.08% |
| EPS Diluted | -48.48% | -253.19% | -72.06% | -31.65% | 2.94% |
| Normalized Diluted EPS | -36.51% | -222.58% | -61.36% | -27.45% | 3.08% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.24% | 0.58% | 0.93% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.24% | 0.58% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
